3D CONSULTANTS WELCOME BILL PULLMAN, PETE VAN ESS AND BRADLEY HARDIMAN TO THE TEAM
We would like to bring you up to date with some recent developments at 3D Consultants as we move into the New Year.
US-based Drs Bill Pullman and Pete Van Ess bring a wealth of pre-clinical and clinical development experience to the team having worked across the entire development phase spectrum through to NDA and together make up our Translational Medicine capability. Both Bill and Pete have a broad appreciation of the regulatory approval process and Pete has a background in PK including PBPK simulation.
Bradley has an extensive background in commercialising research, specialising in early spin-out companies from Universities. Bradley also brings business development and licensing skills to the team.
Our consultancy partnership now benefits from a team of 14 scientists capable of providing expertise and guidance from early discovery through to clinical PoC but now also boasts a capability of being able to advise clients up to NDA. We will be looking to further strengthen the 3D team through 2020.
We would be delighted to hear from you should you require any of our services. Please complete the form on our website with your query.
3D CONSULTANTS WELCOME TIM SPAREY, ALLISON MORGAN, JOANNA SEGIETH AND SUE SNAPE TO THE TEAM
We would like to bring you up to date with some recent developments at 3D Consultants as well as sharing with you some upcoming events.
Tim Sparey will be joining the 3D Consultants team to head up our Business Development activities. Tim is a serial entrepreneur with over 24 years of experience in large pharma and biotech companies with an extensive track record in corporate development, fundraising and business development.
We have recently increased the capability and capacity of our clinical development group with Allison Morgan, Joanna Segieth and Sue Snape joining the team. Sue, Joanna and Allison bring a wealth of experience to the team having worked across a variety of roles and disease areas in early clinical development phases.
Our consultancy partnership now benefits from a team of 13 scientists capable of providing expertise and guidance from early discovery through to and including PoC clinical studies. We will be looking to further strengthen the 3D team through 2019 and will keep you informed as our expertise and experience broadens.
3D Consultants are looking to out-license a GLP tox-ready D1 PAM programme which was divested following the acquisition of Proximagen
Please come and meet us at the Bio2Business event in Basle beginning on the 19th June and Bio Europe in Hamburg through 11-13th November.
Despite the company having been set up less than one year ago, we have already worked with a variety of companies and investors including long term ongoing contracts with BenevolentAI, Syndesi and Proximagen.
DR ISABEL GONZALEZ PRESENTS AS PART OF AN EDUCATIONAL COURSE ON TRANSLATING RESEARCH INTO DRUGS
Please click here for the talk given by Dr Isabel Gonzalez as part of "An Educational Course on Translating Research into Drugs", at the 13th ANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE (Presented by the Alzheimer’s Drug Discovery Foundation), March 17-19, 2019 (Long Beach, CA, USA). You can find all the other talks here.
3DCONSULTANTS STRENGTHENS RELATIONSHIP WITH BENEVOLENTAI
Drug Discovery and Development Consultants Ltd have expanded the working relationship with BenevolentAI. Currently, three 3DC team members are working on BAI projects.
Drug Discovery and Development Consultants Ltd are now members of the OBN network. We will be attending OBN events in the near future. Find more information here.